Hybrid Dosimetry™ and OLINDA / EXM^® 2.0
Organ Specific Dosing

Stockholm - June 10^th 2017

Hermes Medical Solutions Launches Hybrid Dosimetry™ and OLINDA / EXM^® 2.0 at the annual Society of Nuclear and Molecular Imaging meeting SNMMI taking place in Denver CO, June 10-14^th 2017.

Serial radionuclide imaging provides patient specific information for the individual nuclide kinetics in tumors and normal organs to an administered dose. That allows clinicians to personalize further dose to the patient optimizing patient outcome while reducing costs by. Tailoring personalized Targeted Radionuclide Therapy for Peptide Receptor (PRRT) or prostate cancer to absorbed dose limits, requires dosimetry of the highest accuracy.

Hybrid Dosimetry™ and OLINDA / EXM^® 2.0^*, now integrated, offers a comprehensive dosimetry solution that makes patient imaging easier, more efficient and accurate by eliminating errors associated with manually transferring absorbed dose calculations.

Volume delineation of critical organs such as renal cortex, liver, spleen is time consuming when done manually. It has been reported that severe permanent renal toxicity occurs in 9% of cases as late as 1–10 years after PRRT treatment with 90Y-DOTA-octreotide. Hematological toxicity of equivalent severity was also reported in 10% of patients treated with 177LuDOTA-octreotate^**.

The absorbed dose to tumors shows large inter-patient variance and inter-patient variability in kidney dosimetry is too great to justify use of a group-averaged absorbed dose. For patients treated with 177 Lu-DOTA-octreotide, the absorbed dose ranged between 2 and 10 Gy. The absorbed dose to the tumor shows huge inter-patient variance with 177 Lu-DOTA-octreotide and Liver metastases were reported to receive a dose of 167 ± 139 Gy for the first treatment cycle with 7.4 GBq^**.

The Hybrid Dosimetry™ solution allows for faster clinical throughput, from imaging to performing MIRD absorbed dose calculations and includes:

• Hybrid Dosimetry™ for organ delineation and residence time calculation
• OLINDA / EXM^® 2.0 for MIRD based dosimetry

 

^*OLINDA/EXM^® 2.0 is under review by FDA, 510(k) pending; not available for sale in the United States and no sales orders may be taken. OLINDA/EXM^® 2.0 is available in the EU and Canada.

^**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991004/pdf/40336_2014_Article_54.pdf

About Hermes Medical Solutions
Hermes Medical Solutions holds more than 40 years of recognition for Clinical Excellence and innovation in Molecular Imaging. Hermes delivers Enterprise Class systems and software for integrating, visualizing, processing and archiving imaging data from different imaging modalities and devices within Molecular Imaging and Radiology. Hermes solutions are empowering physicians by enabling a faster and more accurate diagnosis of patients, thereby improving quality and efficiency for healthcare provider’s clinical decision making.

CONTACT

BENOIT GALARNEAU
Director Strategic Marketing